Cyanovirin-N produced in rice endosperm offers effective pre-exposure prophylaxis against HIV-1BaL infection in vitro

Plant Cell Reports

Volumn 35, Issue 6, 2016, Pages 1309-1319

  Vamvaka, E ^a   Evans, A ^b   Ramessar, K ^c   Krumpe, L R H ^c,d   Shattock, R J ^b   O'Keefe B R ^c   Christou, P ^a,e   Capell, T ^a  

^a UNIVERSITY OF LLEIDA   (Spain)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Anti HIV; Cyanovirin N; Endosperm; Microbicide; Rice crude extract

Indexed keywords

BACTERIAL PROTEIN; CARRIER PROTEIN; CYANOVIRIN N; PLANT EXTRACT;

DOSE RESPONSE; DRUG EFFECTS; ENDOSPERM; ENZYME LINKED IMMUNOSORBENT ASSAY; HELA CELL LINE; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; METABOLISM; ORYZA; PHYTOTHERAPY; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES; SERODIAGNOSIS; TRANSGENIC PLANT;

BACTERIAL PROTEINS; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSPERM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HELA CELLS; HIV INFECTIONS; HIV-1; HUMANS; IN VITRO TECHNIQUES; NEUTRALIZATION TESTS; ORYZA; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, GENETICALLY MODIFIED; PRE-EXPOSURE PROPHYLAXIS;

EID: 84961768937     PISSN: 07217714     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00299-016-1963-5     Document Type: Article

References (74)

1. Alexandre KB, Gray ES, Mufhandu H, McMahon JB, Chakauya E, O’Keefe BR, Chikwamba R, Morris L (2012) The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. Virology 423:175–186
2. Alexandre KB, Moore PL, Nonyane M, Gray ES, Ranchobe N, Chakauya E, McMahon JB, O’Keefe BR, Chikwamba R, Morris L (2013) Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. Virology 446:66–76
3. Balzarini J (2006) Inhibition of HIV entry by carbohydrate-binding proteins. Antiviral Res 71:237–247
4. Bobardt MD, Armand-Ugón M, Clotet I, Zhang Z, David G, Este JA, Gallay PA (2004) Effect of polyanion-resistance on HIV-1 infection. Virology 325:389–398
5. Botos I, Wlodawer A (2005) Proteins that bind high-mannose sugars of the HIV envelope. Prog Biophys Mol Biol 88:233–282
6. Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O’Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera MI, Laurencot CM, Currens MJ, Cardellina JH, Buckheit RW, Nara PL, Pannell LK, Sowder RC, Henderson LE (1997) Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 41:1521–1530
7. Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, Shattock RJ (2009) Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J Gen Virol 90:234–243
8. Carlson JM, Schaefer M, Monaco DC, Batorsky R, Claiborne DT, Prince J, Deymier MJ, Ende ZS, Klatt NR, DeZiel CE, Lin TH, Peng J, Seese AM, Shapiro R, Frater J, Ndung’u T, Tang J, Goepfert P, Gilmour J, Price MA, Kilembe W, Heckerman D, Goulder PJ, Allen TM, Allen S, Hunter E (2014) HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science 345:1254031
9. Christou P, Ford TL, Kofron M (1991) Genotype-independent stable transformation of rice (Oryza sativa) plants. Biotechnology 9:957–962
10. Colgan R, Atkinson CJ, Paul M, Hassan S, Drake PMW, Sexton AL, Santa-Cruz S, James D, Hamp K, Gutteridge C, Ma JK (2010) Optimisation of contained Nicotiana tabacum cultivation for the production of recombinant protein pharmaceuticals. Transgenic Res 19:241–256
11. Colleluori DM, Tien D, Kang F, Pagliei T, Kuss R, McCormick T, Watson K, McFadden K, Chaiken I, Buckheit RW, Romano JW (2005) Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development. Protein Expr Purif 39:229–236
12. Connor RI, Mohri H, Cao Y, Ho DD (1993) Increased viral burden and cytopathicity correlate temporally with CD4 T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol 67:1772–1777
13. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR (1997) Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185:621–628
14. De Hoff PL, Brill LM, Hirsch AM (2009) Plant lectins: the ties that bind in root symbiosis and plant defense. Mol Genet Genom 282:1–15
15. De Mejía EG, Prisecaru VI (2005) Lectins as bioactive plant proteins: a potential in cancer treatment. Crit Rev Food Sci Nutr 45:425–445
16. Dey B, Lerner DL, Lusso P, Boyd MR, Elder JH, Berger EA (2000) Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 74:4562–4569
17. Drake PM, Barbi T, Sexton A, McGowan E, Stadlmann J, Navarre C, Paul MJ, Ma JK (2009) Development of rhizosecretion as a production system for recombinant proteins from hydroponic cultivated tobacco. FASEB J 23:3581–3589
18. Drake PM, de Moraes Madeira L, Szeto TH, Ma JK (2013) Transformation of Althaea officinalis L. by Agrobacterium rhizogenes for the production of transgenic roots expressing the anti-HIV microbicide cyanovirin-N. Transgenic Res 22:1225–1229
19. Este JA, Schols D, De Vreese K, Van Laethem K, Vandamme AM, Desmyter J, De Clercq E (1997) Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol Pharmacol 52:98–104
20. Fischer R, Stöger E, Schillberg S, Christou P, Twyman RM (2004) Plant-based production of biopharmaceuticals. Curr Opin Plant Biol 7:152–158
21. François KO, Balzarini J (2012) Potential of carbohydrate-binding agents as therapeutics against enveloped viruses. Med Res Rev 32:349–387
22. Gao X, Chen W, Guo C, Qian C, Liu G, Ge F, Huang Y, Kitazato K, Wang Y, Xiong S (2010) Soluble cytoplasmic expression, rapid purification, and characterization of cyanovirin-N as a His-SUMO fusion. Appl Microbiol Biotechnol 85:1051–1060
23. Garg AB, Nuttall J, Romano J (2009) The future of HIV microbicides: challenges and opportunities. Antivir Chem Chemother 19:143–150
24. Giomarelli B, Provvedi R, Meacci F, Maggi T, Medaglini D, Pozzi G, Mori T, McMahon JB, Gardella R, Boyd MR (2002) The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. AIDS 16:1351–1356
25. Goldstein IJ, Poretz RD (1986) Isolation, physicochemical characterization, and carbohydrate binding specificity of lectins. In: Liener IE, Sharon N, Goldstein IJ (eds) The lectins: properties, functions, and applications in biology and medicine. Academic Press, New York, pp 33–248
26. Grivel JC, Shattock RJ, Margolis LB (2011) Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J Transl Med 9(Suppl 1):S6. doi:10.1186/1479-5876-9-S1-S6
27. Gulakowski RJ, McMahon JB, Staley PG, Moran RA, Boyd MR (1991) A semiautomated multiparameter approach for anti-HIV drug screening. J Virol Methods 33:87–100
28. Gustafson KR, Sowder RC, Henderson LE, Cardellina JH, McMahon JB, Rajamani U, Pannell LK, Boyd MR (1997) Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum. Biochem Biophys Res Commun 238:223–228
29. Haase AT (2011) Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 62:127–139
30. Hladik F, Hope TJ (2009) HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 6:20–28
31. Hu Q, Mahmood N, Shattock RJ (2007) High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 368:145–154
32. Huang X, Jin W, Griffin GE, Shattock RJ, Hu Q (2011) Removal of two high-mannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin. J Gen Virol 92:2367–2373
33. Jekle A, Keppler OT, De Clercq E, Schols D, Weinstein M, Goldsmith MA (2003) In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J Virol 77:5846–5854
34. Kumar KK, Chandra KL, Sumanthi J, Redd GS, Shelar PC, Reddy B (2012) Biological role of lectins: a review. J Orofac Sci 4:20–25
35. Lagenaur LA, Sanders-Beer BE, Brichacek B, Pal R, Liu X, Liu Y, Yu R, Venzon D, Lee PP, Hamer DH (2011) Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol 4:648–657
36. Liu X, Lagenaur LA, Simpson DA, Essenmacher KP, Frazier-Parker CL, Liu Y, Tsai D, Rao SS, Hamer DH, Parks TP, Lee PP, Xu Q (2006) Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob Agents Chemother 50:3250–3259
37. Ma JK, Drake PM, Christou P (2003) Genetic modification: the production of recombinant pharmaceutical proteins in plants. Nat Rev Genet 4:794–805
38. Madan RP, Mesquita PM, Cheshenko N, Jing B, Shende V, Guzman E, Heald T, Keller MJ, Regen SL, Shattock RJ, Herold BC (2007) Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J Virol 81:7636–7646
39. Mesquita PM, Wilson SS, Manlow P, Fischetti L, Keller MJ, Herold BC, Shattock RJ (2008) Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J Virol 82:6576–6584
40. Mori T, Shoemaker RH, Gulakowski RJ, Krepps BL, McMahon JB, Gustafson KR, Pannell LK, Boyd MR (1997) Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein. Biochem Biophys Res Commun 238:218–222
41. Mori T, Gustafson KR, Pannell LK, Shoemaker RH, Wu L, McMahon JB, Boyd MR (1998) Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. Protein Expr Purif 12:151–158
42. Mori T, Barrientos LG, Han Z, Gronenborn AM, Turpin JA, Boyd MR (2002) Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts. Protein Expr Purif 26:42–49
43. Muntz K (1998) Deposition of storage proteins. Plant Mol Biol 38:77–99
44. Murad A, Cunha N, Lacorte C, Coehlo M, Vianna G, Rech E (2014) Expression, purification and analysis of the anti-HIV Cyanovirin-N produced in transgenic soybeans seeds. BMC Proc 8:105
45. Naqvi S, Zhu C, Farre G, Ramessar K, Bassie L, Breitenbach J, Perez Conesa D, Ros G, Sandmann G, Capell T, Christou P (2009) Transgenic multivitamin corn through biofortification of endosperm with three vitamins representing three distinct metabolic pathways. Proc Natl Acad Sci USA 106:7762–7767
46. O’Keefe BR, Murad AM, Vianna GR, Ramessar K, Saucedo CJ, Wilson, J, Buckheit KW, da Cunha NB, Araújo AC, Lacorte CC, Madeira L, McMahon JB, Rech EL (2015) Engineering soya bean seeds as a scalable platform to produce cyanovirin-N, a non-ARV microbicide against HIV. Plant Biotechnol J 1–9 [pub ahead of print]
47. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. New Engl J Med 338:853–860
48. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West AP Jr, Bjorkman PJ, Wilen CB, Doms RW, O’Brien M, Bhardwaj N, Borrow P, Haynes BF, Muldoon M, Theiler JP, Korber B, Shaw GM, Hahn BH (2013) Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci USA 110:6626–6633
49. Permanyer M, Ballana E, Esté JA (2010) Endocytosis of HIV: anything goes. Trends Microbiol 18:543–551
50. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC (2009) Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol 83:8289–8292
51. Portsmouth SD, Scott CJ (2007) The renaissance of fixed dose combinations: combivir. Ther Clin Risk Manag 3:579–583
52. Ramessar K, Sabalza M, Miralpeix B, Capell T, Christou P (2010) Can microbicides turn the tide against HIV? Curr Pharm Des 16:468–485
53. Sabalza M, Vamvaka E, Christou P, Capell T (2013) Seeds as a production system for molecular pharming applications: status and prospects. Curr Pharm Des 19:5543–5552
54. Sacchettini JC, Baum LG, Brewer CF (2001) Multivalent protein-carbohydrate interactions. A new paradigm for supermolecular assembly and signal transduction. Biochemistry 40:3009–3015
55. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M (1992) Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 66:1354–1360
56. Sexton A, Drake PM, Mahmood N, Harman SJ, Shattock RJ, Ma JK (2006) Transgenic plant production of Cyanovirin-N, an HIV microbicide. FASEB J 20:356–358
57. Sexton A, Harman S, Shattock RJ, Ma JK (2009) Design, expression, and characterization of a multivalent, combination HIV microbicide. FASEB J 23:3590–3600
58. Shattock RJ, Moore JP (2003) Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 1:25–34
59. Shattock RJ, Rosenberg Z (2012) Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med 2:a007385
60. Shenoy SR, O’Keefe BR, Bolmstedt AJ, Cartner LK, Boyd MR (2001) Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. J Pharmacol Exp Ther 297:704–710
61. Shenoy SR, Barrientos LG, Ratner DM, O’Keefe BR, Seeberger PH, Gronenborn AM, Boyd MR (2002) Multisite and multivalent binding between cyanovirin-N and branched oligomannosides: calorimetric and NMR characterization. Chem Biol 9:1109–1118
62. Stöger E, Fischer R, Moloney M, Ma JK (2014) Plant molecular pharming for the treatment of chronic and infectious diseases. Annu Rev Plant Biol 65:743–768
63. Sudhakar D, Duc LT, Bong BB, Tinjuangjun P, Maqbool SB, Valdez M, Jefferson R, Christou P (1998) An efficient rice transformation system utilizing mature seed-derived explants and a portable, inexpensive particle bombardment device. Transgenic Res 7:289–294
64. Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Mtimavalye LA, Yang LP, Liomba GN, Broadhead RL, Chiphangwi JD, Miotti PG (1998) Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 12:1699–1706
65. Takaiwa F, Hirose S, Takagi H, Yang L, Wakasa Y (2009) Deposition of a recombinant peptide in ER-derived protein bodies by retention with cysteine-rich prolamins in transgenic rice seed. Planta 229:1147–1158
66. Valdez M, Cabrera-Ponce JL, Sudhakar D, Herrera-Estrella L, Christou P (1998) Transgenic central American, west African and Asian elite rice varieties resulting from particle bombardment of foreign DNA into mature seed-derived explants utilizing three different bombardment devices. Ann Bot 82:795–801
67. Vamvaka E, Arcalis E, Ramessar K, Evans A, O’Keefe BR, Shattock RJ, Medina V, Stöger E, Christou P, Capell T (2016a) Rice endosperm is cost-effective for the production of recombinant griffithsin with potent activity against HIV. Plant Biotechnol J. doi:10.1111/pbi.12507
68. Vamvaka E, Twyman RM, Murad AM, Melnik S, Teh AYH, Arcalis E, Altmann F, Stöger E, Rech E, Ma JKC, Christou P, Capell T (2016b) Rice endosperm produces an underglycosylated and potent form of the HIV-neutralizing monoclonal antibody 2G12. Plant Biotechnol J 14:97–108
69. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896–1905
70. Wei X, Hunt G, Abdool Karim SS, Naranbhai V, Sibeko S, Abdool Karim Q, Li JF, Kashuba AD, Werner L, Passmore JA, Morris L, Heneine W, Johnson JA (2014) Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial. J Infect Dis 209:1916–1920
71. Weis WI, Drickamer K (1996) Structural basis of lectin-carbohydrate recognition. Annu Rev Biochem 65:441–473
72. Xiong S, Fan J, Kitazato K (2010) The antiviral protein cyanovirin-N: the current state of its production and applications. Appl Microbiol Biotechnol 86:805–812
73. Yamagata H, Tanaka K (1986) The site of synthesis and accumulation of rice storage proteins. Plant Cell Physiol 27:135–145
74. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD (1993) Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179–1181